TELA Bio (NASDAQ:TELA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01, Zacks reports. TELA Bio had a negative net margin of 60.49% and a negative return on equity of 556.18%. The firm had revenue of $17.65 million during the quarter, compared to analyst estimates of $23.17 million. TELA Bio updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.
TELA Bio Price Performance
TELA stock traded down $0.07 during midday trading on Monday, hitting $1.40. The company's stock had a trading volume of 721,627 shares, compared to its average volume of 212,429. The firm has a market capitalization of $55.14 million, a price-to-earnings ratio of -0.83 and a beta of 1.10. The company has a quick ratio of 1.81, a current ratio of 2.62 and a debt-to-equity ratio of 14.22. TELA Bio has a 12 month low of $1.28 and a 12 month high of $6.50. The company has a 50 day moving average of $2.56 and a two-hundred day moving average of $2.70.
Analyst Ratings Changes
TELA has been the topic of several analyst reports. Piper Sandler downgraded TELA Bio from an "overweight" rating to a "neutral" rating and lowered their target price for the company from $5.00 to $2.00 in a research report on Friday. Canaccord Genuity Group lowered their price objective on TELA Bio from $12.00 to $7.00 and set a "buy" rating on the stock in a research report on Friday.
Get Our Latest Analysis on TELA Bio
About TELA Bio
(
Get Free Report)
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Featured Stories
Before you consider TELA Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.
While TELA Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
